AstraZeneca's Iressa Produces Effect In Subpopulation, ASCO Data Show
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial Phase II study shows 62% response rate in Korean, non-smoking females with non-small cell lung cancer. Identification of Iressa (gefitinib) responders and the role of EGFR mutations are major themes at the American Society of Clinical Oncology annual meeting.